End Of Phase I Results Of Zuma-3, A Phase 1/2 Study Of Kte-X19, Anti-Cd19 Chimeric Antigen Receptor (Car) T Cell Therapy, In Adult Patients (Pts) With Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (All).